The costs of transporting end-stage renal disease (ESRD) patients to dialysis centers are high and growing rapidly. Research has suggested that substantial cost savings could be achieved if medically appropriate transport was made available and covered by Medicare.
Background
Among the chronically ill, travel for medical care can be burdensome from both a time and cost perspective, and may be an important factor in treatment decisions and patient outcomes. [1] [2] [3] Travel costs may be especially high for people with end-stage renal disease (ESRD) who receive hemodialysis, as these patients typically have to travel for outpatient treatment three times per week, every week of the year, generally for the remainder of their lives. The high cost of transport for hemodialysis patients is not only due to the frequency of travel, but also driven by the physical assistance needs of this population. Dialysis patients have an average of 3.2 comorbidities, 4 51% are over age 65, 5 over one-third use a wheelchair or a walker and half require some type of mobility device. 6 Due to the high prevalence of diabetes in this population, many are amputees. At least half are transportation dependent, meaning they cannot drive themselves and are unable to take public transit. 6 The costs of transporting this very ill, elderly and largely non-ambulatory population for medical care are high and growing rapidly. In 2009, Medicare spent $930 million on ambulance transports alone for ESRD patients; 7 a 60% increase over 2005 expenditures. Patients or secondary insurers paid an additional 25% or another $230 million, for a total cost of nearly $1.2 billion in 2009. Medicare's recent cost containment efforts in the ESRD program have largely focused on outpatient dialysis and injectable drugs. However, total expenditures for these services increased by only about 4% per year between 2005 and 2010. 5 During this same period, the cost of ambulance transports for ESRD patients rose at an average annual rate of 15%. 7 Medicare does not pay for any transportation services except ambulances, which are only covered when deemed medically necessary. Therefore, while cost containment efforts have focused primarily on services with low growth trends, the issue of the use of ambulances for transport to routine dialysis has been identified, but not adequately addressed, for at least the past two decades. As early as 1994, the Office of the Inspector General (OIG) was charged with investigating the medical necessity of, and payment practices related to ambulance transportation of dialysis patients. The OIG found that less than 2% of ESRD beneficiaries accounted for 75% of total ESRD ambulance payments. 8 The high expense for so few people was related to the routine use of ambulances for trips to dialysis facilities. OIG also found that 70% of dialysis-related ambulance claims examined did not meet Medicare coverage guidelines for medical necessity because beneficiaries did not have conditions that contraindicated use of another type of transport. 9 A subsequent General Accounting Office (GAO) report showed that more than 50% of rural Medicare ambulance trips were of a non-emergency nature. 10 Other research has suggested that substantial cost savings could be achieved if medically appropriate transport was made available and covered by Medicare. Burkhardt 11 demonstrated that Medicare's transportation policy was not cost-effective, with Medicare often paying for ambulance trips when less expensive, alternative transportation could have been used. Further, Medicare could have saved 96% of what it paid for ambulance transports that were subsequently determined to be non-emergencies. The paper noted that cost was not the only burden that would be relieved if Medicare paid for appropriate types of non-emergency medical transportation (NEMT), as this would greatly simplify the logistics for patients, state programs and health providers. Finally, a 2012 report by the Medicare Payment Advisory Committee (MedPAC) showed that reducing ambulance use for dialysis transport in high-use states to the national median would save $400 million per year. 12 However, these findings and the previous reports from the OIG and GAO did not lead to new legislation that would address the fundamental problem of the lack of Medicare coverage for less expensive alternative transportation.
Given the high costs and rapid growth in the costs of dialysis transportation and the well-documented problems in managing these costs in the Medicare program, the paucity of recent research examining the extent and nature of such costs and their policy implications needs to be addressed. The total annual costs of dialysis transportation in the United States are difficult to estimate. To our knowledge, no comprehensive studies or estimates have been published to date. While estimates are available reporting Medicare costs for ambulance transportation for dialysis patients, as are annual NEMT costs (of which some substantial portion is for dialysis patient transport), transportation costs for other public assistance programs available to dialysis patients and those borne by private insurers and patients and their families are more difficult to estimate, and may be higher than the payments made by Medicare or Medicaid. Therefore, the objectives of this study were (1) to estimate US dialysis transportation costs from a purchaser's perspective, in total, by transport and payer type and by state and region, and (2) to estimate potential cost savings that could be achieved if less expensive means of transport were utilized.
Methods

Data Sources and Approach
This was a retrospective modeling study of dialysis patient travel estimates and the costs of travel, using publicly available data on U.S. dialysis patients and facilities in 2012. Using an actuarial model, the total costs of transportation were estimated for about 360,000 patients for travel to routine in-center dialysis. Per trip travel distance estimates were calculated from patient ZIP codes and dialysis facility addresses. Costs were estimated from a purchaser's perspective, where costs were defined as the total direct financial costs of all types of dialysis transportation incurred by the purchaser(s) of the service. This was either payments made by insurers, patients or other third parties to the transport provider for the actual services used, or, where no transport provider was paid for the transportation service, (i.e., patients drove themselves by private auto), a direct cost was calculated based on standard mileage rates.
Transit service to a dialysis facility is provided by a variety of modes, defined by the type of vehicle used, operating characteristics of the service provided, and the travel needs of the riding public for which they are designed. The transportation categories used in the model are defined in Table 1 . Utilization by transport type used to travel to dialysis and costs of each transport type were estimated from fee schedules, government reports, transportation websites and peer-reviewed literature. The primary data sources and assumptions used in the model are summarized in Table 2 .
Model Design
The model used was an actuarial-type deterministic model, where all inputs were pre-defined, with predetermined application of formulae to the inputs to produce output. Costs were estimated for all in-center dialysis patients in the 50 US states, the District of Columbia and Puerto Rico. The base year for estimates was 2012. Costs were projected forward to 2014 using transportation cost inflation trends 13 and dialysis patient growth trends. 7 Costs were estimated using the following input variables: 
Input variables were detailed by the following dimensions:
• Insurance category (e.g., Medicare, Medicaid, commercial, no insurance); • Transport type (e.g., ambulance, wheelchair van, private auto); • Patient location (e.g., state, urban versus rural); and • Calendar year. The full matrix of detailed cost estimates across all model dimensions included thousands of data points. Each data point was estimated using actuarial techniques through a combination of detailed estimates and higher level adjustment factors. For example, an average cost per trip for ambulettes was modified by an insurance-type factor to differentiate what Medicaid would pay versus what a patient would pay out-ofpocket. Detailed utilization estimates (i.e., treatments, transport miles) by transport type and insurance category were also calculated by applying utilization proportions to the detailed estimates of patients, miles, and visits that were derived from the distance calculations. The output from distance calculations was miles per treatment and patient counts by ZIP code.
Each detailed estimate was then broken down by insurance category and transport type based on higher level estimates for the general population. A further delineation of each cost estimate was made by applying payment allocation factors to each insurance category-by-transport type, reflecting the insurance benefits for each transport type in each insurance category. For example, Medicare pays 80% of the allowable costs of ambulance services. The remainder is paid by third parties such as Medicaid (for dual eligible beneficiaries), private insurance or the patients themselves.
Patient Travel Estimates (distance calculations)
To estimate patient travel distances for dialysis, two data points were estimated: (1) patient residence and (2) dialysis treatment destination. These data points were mapped to latitude and longitude coordinates using Microsoft MapPoint 2011 and GPS Visualizer software. Driving distances and times were calculated using custom software developed in MapPoint and Wolfram Mathematica 8. Patient address data were limited to ZIP code of residence. Patients were assigned to residential locations within their ZIP code, weighted by population density. For example, an urban center within a ZIP code received a higher allocation of patients than a rural area of the same size within the same ZIP code.
Data on each patient's actual facility were not obtained. It was assumed that the facility location closest to the patient residence was the one utilized. This assumption is commonly used in studies of dialysis access. [14] [15] [16] However, initial modeling of patient assignments to their nearest facility revealed that such an assumption produced unrealistic patient counts at many facilities. Many facilities would be heavily overor under-allocated, relative to the actual number of patients served by these facilities. To address this problem, the model's initial patient assignment results were compared with reported patient census counts from Medicare Cost Reports 17, 18 and Dialysis Facility Reports, 4 and the model-assigned patient counts were "corrected" by randomly selecting patients from over-allocated facilities and re-assigning them to other nearby facilities so that the number of patients assigned to each facility in the model achieved a 90% correlation with the actual patient counts reported by facilities.
Comparisons with point estimates found in recent literature on U.S. patient travel for dialysis services [19] [20] [21] were made to validate the estimates of patient travel distance and time to dialysis facilities made for this study.
Statistical Analysis
Study Outcomes
Transportation costs, trips and miles were estimated nationally, by state, census region and ESRD network for urban, rural and super-rural subgroups, by transport type and payer. Rates were calculated for average costs per patient, per round-trip and per mile. Costs were cumulated over 3 years -2012 through 2014.
Reliability and Validity
Three sets of comparisons were made between model estimates and other cost estimates from the literature: (1) total national costs of dialysis transportation, (2) Medicare payments for ambulances, and (3) NEMT costs per trip. In general, the estimates from this study were conservative by comparison to the other estimates available from the literature. Model estimates were 7% to 12% lower than the comparison figures.
For example, the model estimate of 2012 Medicare ambulance payments per patient for routine dialysis transportation was approximately 8% lower than those calculated from the 2009 actual Medicare ambulance payments (trended for inflation).
Cost Saving Scenarios
In addition to the baseline estimates, cost estimates and potential cost savings were calculated for three scenarios in which utilization of higher cost means of transport was shifted to less expensive transport types. The three scenarios tested were:
• Scenario 1: Reduce ambulance utilization to 1% of trips. In the baseline model, seven states had ambulance use below 1% of total trips. This scenario calculated the savings that would result if all states had ambulance utilization of 1% of trips, and excess ambulance trips were proportionally allocated to all other modes except self-transport.
• Scenario 2: Change the mix of non-ambulance commercial NEMT transports (i.e., ambulettes, wheelchair vans, taxis and public transit) to a lower cost mix based on local "best practices". In the baseline estimates, the national average mix of transports within these four categories was 7%, 54%, 29%, and 10%, respectively. The mix used in this scenario was 5%, 25%, 60%, and 10%, respectively. It was assumed that public transit use could not be higher than the national average, due to limited availability in rural areas and access problems for most dialysis patients. Reducing ambulette and wheelchair van use to 30% of this total from the national average of 61% may be aggressive when compared to current practices. It was assumed that some ambulette trips could be shifted to wheelchair vans, and most wheelchair van trips could be shifted to taxis.
• Scenario 3: Combine the utilization shifts from Scenarios 1 and 2, first shifting excess ambulance use proportionally to all other modes except self-transport, and then shifting the mix within commercial NEMT to the proportions in Scenario 2.
Sensitivity Analysis
A series of one-way sensitivity analyses were conducted for the 3-year (2012-2014) projected costs of dialysis transportation for in-center dialysis patients, to determine the key cost drivers estimated in the model. Eight variables expected to show sensitivity in the results to changes in their values were identified in the model. The effects of changes from the baseline assumption for each single variable in the analysis were isolated in the model by holding all other factors constant (at baseline estimates) and then modifying the test variable through a range of reasonable alternate assumptions. Model results for total (cumulative) costs under these alternate assumptions were compared to the baseline result. Plausible ranges of values were developed from the literature and/or from sub-analyses to bound the one-way sensitivity analyses. Sources and rationales for the assumptions used are given in Table 3 . 7 The baseline assumption was 6.8% annual growth, which was the average of the past 3 years.
Results
The study cohort used in the model included 360,579 in-center dialysis patients assigned to 5,405 dialysis centers (Table 4 ). These patients could not be assigned to a dialysis facility, since the model allocated them to geographically inaccessible areas (e.g. wilderness areas and bodies of water). d 61 facilities had no patients assigned as the closest facility.
The estimated annual cost of transportation to dialysis in the United States for 2012 was $3.0 billion, approximately half of which was for ambulance transport. Most of the remaining costs were for use of commercial transport via ambulettes, wheelchair vans and taxi services. Only about 5% of costs were related to use of private vehicles or public transportation. Costs were expected to grow to $3.4 billion by 2014 ( Table 5 ).
Figure 1. Dialysis Transportation Cost PPPY and Percent of Trips by Ambulance, by State
The correlation was calculated from state-level observations, using the percent of total trips that were via ambulance correlated with total costs PPPY.
There was also high regional variation, with PPPY costs of $7,119 in the Midwest versus $9,780 in the Northeast (Figure 2 ). The percentage of costs attributed to ambulances was 39% in the Midwest and 56% in the Northeast.
Figure 2. Dialysis Transportation Costs PPPY and Percent of Costs Attributable to Ambulance Trips, by Census Region
Sensitivity Analysis Figure 3 shows the results of the one-way sensitivity analysis. The largest effects on the model cost estimates resulted from the assumptions of utilization mix by type of transport. The range of results varied from 16% below baseline to 20% above baseline when the utilization patterns of individual US regions were substituted for the overall US average pattern. The average cost per trip for NEMT services, the level of insurer discounts from charges, and the average miles driven per trip also showed large effects. Other variables had very small effects by comparison. 
Savings Estimates
Potential cost savings that may be achieved over 3 years under various scenarios of changes in service utilization mix are shown in Table 8 . Changing the mix of services within the four non-ambulance commercial transport categories (ambulettes, wheelchair vans, taxis and public transit) to a lower cost mix of 5% ambulettes, 25% wheelchair vans, 60% taxi and 10% public transit would save nearly $1 billion, or 10% of total costs over 3 years, versus the baseline utilization mix in the model. Shifting patients from costly ambulance transport to less expensive modes of transport offers the potential for dramatic savings. If ambulance use dropped to 1% of trips from the current 5% of trips, the savings would be over $3.2 billion, or one-third of total costs, over the 3-year period. Combining the utilization shifting strategies of the first two scenarios could save $4.2 billion, or 44% of total costs over 3 years. 
Discussion
This study estimated that the costs of transport to routine dialysis for US patients are approximatley $3.0 billion annually and growing rapidly, especially Medicare ambulance costs. The study further showed that if regional or state-level "best practices" were implemented nationally, costs could be cut by one-third or more, saving billions of dollars over 3 years. Despite the apparent high costs of dialysis transportation, this cost segment has received very little attention relative to its overall impact on ESRD costs. For example, concern over the high costs of dialysis drugs arguably led to an entire re-design of Medicare's payment system for dialysis. 22 Yet the costs of ambulances for ESRD patients were rising at a much faster rate than dialysis drug costs and rapidly approached $1 billion per year by 2009 (Table 9 ). In response to the 2012 MedPAC report on Medicare payment for ambulance services, 12 Congress took action in the American Taxpayer Relief Act of 2012 (the so-called "Fiscal Cliff " act) to attempt to restrain the use of ambulances for dialysis transport. The new law cut fee schedule payments for non-emergency basic life support services involving transport of an individual with ESRD to a dialysis facility by 10%, effective October 1, 2013. 23 Reduced payments should be a disincentive to ambulance providers to transport dialysis patients, but coverage of any alternative means of transport was not addressed. A major policy issue that should be addressed is to determine how to reduce transportation costs without shifting the cost burden to the patient, to the dialysis provider, or to tax-funded public transportation programs. There is already a heavy burden of costs borne by patients, their families and public transit services. This study estimated that approximately one-third of total costs are not covered by patients' primary or secondary insurance. Patients who do not have access to public transportation assistance programs may face a large financial burden due to transport to and from dialysis three times per week. Access to needed services may be reduced or eliminated for some patients, purely based on costs.
Citing budget constraints and the growing demand for dialysis transport, some community transportation services are already turning away dialysis patients. 24 Not only is the prevalent dialysis patient population growing, but also there is growing evidence for the health benefits of short daily hemodialysis versus traditional three-times weekly treatment. [25] [26] [27] [28] Added to this is a trend toward more off-hours appointment times, especially at the centers run by the largest dialysis organizations. These factors, taken together, could precipitate more service cutbacks or shortfalls for budget-constrained county and municipal paratransit services. The transportation that many dialysis patients rely on may no longer be available. Concern in some states over this pending crisis of increasing demand in the face of shrinking budgets is high enough that congressmen are taking action to address the problem. At least two bills were introduced in 2012 (H.R. 6011 and S. 2163) to address barriers in accessing quality care for people with kidney failure, including transportation issues. 29 Policy issues, such as Medicare's limited transportation benefits, and budget cuts to state Medicaid programs and county and municipal transit services, may combine to create a serious crisis in care for dialysis patients. One opportunity to address the issue is through the Dual Eligible demonstration projects funded by the Affordable Care Act. With at least half of the 50 states expected to participate, the ability to coordinate transportation benefits between Medicare and Medicaid for dialysis patients could save a lot of money, and more importantly, protect vital access to medical services for dialysis patients. Another opportunity may result from the ESRD demonstration projects that are under consideration by the Centers for Medicare and Medicaid Services (CMS). In a recent Open Door Forum held by CMS on ESRD demonstration projects, several participants commented on the need to address transportation services. 30 This study was primarily limited by the lack of quality and the incompleteness of the data used to generate estimates. We are unaware of any systematic reporting on dialysis transportation costs in the United States. There are unreported costs, such as data on the number of patient-driven miles; and information on transportation type used by dialysis patients is very limited. The cost estimates in this study appear to be conservative, when compared with other available literature, and may have underestimated the actual costs by 10% or more. Some model assumptions were generalized across geographic regions, where variation may exist. This limits the reliability of the detailed estimates at the state or region level.
Few studies have been published that attempt to examine overall US dialysis transportation costs and utilization across all transport types and payers. This study begins to explore the range of probable costs and associated policy issues in dialysis transportation. However, higher quality data are needed to more thoroughly address this largely ignored but growing segment of ESRD costs. There are significant savings opportunities that will improve quality of care and protect patient access. Study of these opportunities deserves more attention from policy-makers, especially in the current environment of tightening federal, state, and local budgets that fund much of this care.
